Introduction
The oxazaphosphorines cyclophosphamide GY, 2-(bis-[Z-chloroethyl] -amino)tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide and ifosfamide IF, 3-([2-chloroethyll-2-C-[2-chloroethyllamino)-tetrahydro-2H -1,3,2-oxazaphosphorine-2 -oxide are amongst the most widely used drugs in cancer chemotherapy [ l ] . The drugs are inactive per se: activation by liver enzymes results in formation of alkylating products with structures related to mustard [ 11. The mutagenic mustard-related structures induce DNA damage whereas other metabolites such as acrolein are believed to be responsible for the urotoxic properties and/or neurotoxic symptoms. In both routine cancer therapy and experimental cancer research, many people might be exposed to CY and IF during pharmaceutical handling of the agents.
No methods are yet available for the routine screening of uptake of IF, CY, and mustard-related compounds during exposure to oxazaphosphorines: as a result, the risks to nurses and physicians working in clinical oncology, and pharmacists and to researchers working in cancer research, cannot yet be estimated.
The hazards of exposure to oxazaphosphorines may be estimated by use of any one of several methods for the determination of the mutagenic activity of biological fluids containing mustards; the methods, however, either lack a link with uptake of unchanged, inactive oxazaphosphorines or are laborious and requiIe extensive sampling of biological fluids [2] .
An analytical method for routine determination of CY, IF, and their toxic products should be (a) highly sensitive, since these compounds are present at low nanogram levels per mL of biological fluid and 10-100 pL of blood (fingertip) or urine should be sufficient for 2 determinations, and (b) highly selective since a large number of mustard-related metabolites might be present [l] . In addition, the analytical system must be highly deactivated, since some mustard compounds are notoriously reactive and readily adsorbed by active surfaces.
Existing methods for the determination of oxazaphosphorines in biological fluids have recently been reviewed [3] : bioanalysis of CY and IF has been performed by both gas and high performance liquid chromatographic methods, some of which are also suitable for determination of active metabolites. The methods enable adequate monitoring of patients treated with CY and IF but lack the sensitivity required for trace analysis.
If oxazaphosphorines are analyzed by capillary GC-MS, derivatization may not be essential [4] ; preliminary experiments in our laboratory have shown that the compounds could be determined in water without any sample pretreatment simply by dilution of only 1-5 pL of the sample to 1 mL with ethyl acetate [4] . We extended these observations to biological fluids and it appeared that both CY and IF could be easily determined in blood below the ng/ml level. This report presents, for the first time, an analytical method for the determination of trace quantities of CY and IF, and some of their metabolites, in biological fluids. The capacity of the method for estimating the risks of handling oxazaphosphorines by persons involved in health care and cancer research is described in detail.
Experimental

Instrumentation and Reagents
Gas chromatographic determination was performed by both electron capture and flame ionization detection.
GC-ECD was used for determination of the compounds of interest at pg/mL levels, and also traces of metabolites of the oxazaphosphorines, such as nor-N-mustard formed from CY. The analysis was accomplished with a Hewlett-Packard 5890 gas chromatograph equipped with ECD (63Ni, 56. Samples were introduced by on-column injection: helium was used as carrier gas at a flow rate of 5 mL/min and the oven temperature was programmed from 85 to 100 "C at 16/min, then to 160 "C at 50"/min, and finally at 5"/min to 220 "C, which was maintained for 5 min (the temperature program was slightly modified for analysi.; of the oxazaphosphorine metabolites) The Samples were introduced by on-column inlection and the oven temperature was programmed from 85 to 100 "C at 15"imin then to 160 "C at 50"/min then to 180 "C at l"/min, and finally to 220 "C at 5"imin Data were acquired by a Spectra-Physics 4290 integra tor
The mustard analogs of interest were obtained from ASTA Pharma AG (Frankfurt, FRG) and were used without further purification CompIessed gases were UHP grade, additionally purified with gas filter traps AR grade sodium hydroxide and ethyl acetate were purchased from E Merck (Darmstadt FRG) ethyl acetate was distilled twice before use
Adsorption Traps: Solid Phase Extraction (SPE)
A rapid and simple method for the isolation of IF and CY from biological fluids has recently been described 151 Adsorption sample traps were prepared from cyclohexyl-bonded silica and were used for IF and CY concentrations between 10 ng/mL and 100 pgimL linear calibration curves were obtained (r > 0 9994) Once packed each trap was eluted with p a grade metnanol (50 mL, Merck) and dried with helium (50 mLimin) for 1 h at ambient temperature Traps could be stored 111 the f r e e~e r at Ethyl acetate (100 pL) was added to the patient plasma sample (10 pL), the sample was mixed and centrifuged, and 1 pL of the organic layer was subsequently analyzed by GC-ECI). Evaporation and concentration was necessary with rat plasma owing to the low concentration of CY in the sample: the patient sample contained 12.7 pg/mL IF; that from the rat contained only 2 ng/mL.
The patient plasma was also analyzedby SPE. The chromatograni then obtained was not essentially different from that obtained following LLE. the concentration then measured was 13.4 pg/ml. and interfaced with a Hewlett-Packard 9825B data system Electron ionization mass spectra at 70 eV were obtained at a rate of 2is Samples were inlected splitless (spht valve closed for 30 s)
GC-MS
at 60 "C the oven was then ballistically heated to 150 "C which was maintained for 2 min and then programmed from 150 "C to 300 "C at 10"/mm The column head pressure was 20 0 psi and the interfdce temperature 290 "C GC-MS was also used for random control of patient samples
Recoveries
The efficiency of the analytical procedure was determined by loading plasma and urine samples with 10 pL aliquots of IF and CY standards in water and extracting the samples by LLmE as described above. The recoveries and relative standard deviations for spiked plasma samples over a wide range of concentrations are presented in Table 1 , data obtained from spiked urine samples were similar.
The recovery of IF and CY from biological fluids was examined during the early stages of this work and shown always to be above 85 %. Linear calibration curves (? > 0.9992) were obtained in the range depicted in Table 1 . Recovery studies also showed that extracts of IF and CY could be stored for 8 weeks at -20 "C and 24 hours at room temperature. Slight reductions in the recovery figures were noted when extracts were stored for 8 weeks or more at 4 "C (loss ca 10 %).
When IF and CY concentrations were above 44 ng/mL, e.g. for experimental drug monitoring [61, we preferred to use GC-FID
Journal of High Resolution Chromatography Table 1 Recovery of IF and CY from plasma (pg/mL-nglmL range). because the calibratiori curves obtained for plasma and urine were linear over a wider range than those obtained by GC-ECD.
Analysis of Biological Samples
This method has been applied to the analysis of (a) micro volumes (10-50 pL) of blood samples taken from patients and animals treated with IF and CY during the first 48 houis after starting treatment and (b) traces of IF and CY in 100 pL-1 mL volumes of blood of different origin. Concentrations of 1F and CY in samples collected during the first two days were so high that GC-FID could be used for routine monitoring of the drug; the GC-ECD system, however, required only micro volumes of blood. This i s of particular interest for routine monitoring of oxazaphosphorines in pediatric sessions (blood from childrens' fingertips) and in small laboratory animals.
The method seems to be particularly useful for monitoring patients subjected to lorig term oral CY treatment for breast cancer (CMF) 19, 101. Patient compliance can be determined bi-weekly by analysis of fingertip blood samples and dose adjustments can then be made on the basis of systemic measurements of CY levels and the development of toxic effects [9, lo] . When 1000 mg doses of CY were administered 1.v. to such patients, application of the method showed blood concentrations to be in the range 170 ng/mL-40 pgimL during the first 48 hours (n = 19). Six days after administration the CY concentration (12-256 pgimL) had dropped to well below the ngiml level: 1 mL of blood was required for determination of the latter concentration.
As far as we know, this is the first time that the latter concentrations have been determined routinely. The data clearly denionstrate the applicability of the GC-ECD method to the determination of trace levels of oxazaphosphorines: the limits of determination, using 1 mL samples of blood plasma, are 10 pg/mL and 6 pg/mL for CY and IF respectively (signal to noise ratio: 3 : 1).
The method has also been applied to the monitoring of trace levels of IF and CY in rats to which the oxazaphosphorines were at t = 5 min post-administration 161) down to 16 pg/mL (t = 48 h post-administration). 1 mL of blood was required for determination of the latter concentration.
The method has also been used to determine trace levels of IF and CY ir. samples collected from nurses working with IF or CY for two months in oncological environments. Thus far no detectable levels of IF or CY have been demonstrated in 1 mL samples of the body fluids of interest (n = 6). This study is continuing in order to VOL. 14, DECEMBER 1991 increase the number of individuals included (n > 100). A detailed report of these data, and the implications with regard to mutagenicity, will be published elsewhere. This method will be useful in other areas of cancer research for determining the risks associated with the handling of cytotoxic drugs. Most importantly, the presence of trace levels of IF, CY, and their metabolites can now be related to mutagenic effects by comparing data of sister chromatid exchanges (SCE) induced by exposure of CHO cells to biological fluids containing the compounds of interest 1111. This will finally result in a definition of the "mutagenic levels" of CY, IF, and/or their metabolites in hunans.
Introduction
Formyldienolone (androsta-1,4-diene-Z-carboxaldehyde-11,17-dihydroxy-l7-methyl-3-oxo-(lla,l7~); CzlH2804; RN 2454-11-7), an anabolic steroid with therapeutic uses and low androgenic properties, is an ingredient of the Italian pharmaceutical product "Esiclene". It can, however, also be used illegally in sport with the aim of enhancing athletic performance. Studies of its chemical and pharmacological properties have been reported [1] [2] [3] and toxicological investigation has also been performed i 4 1
The detection of anabolic steroids and their metabolites in human urine is generally performed by GC-MS, usually after formation of a suitable derivative [5-111. This paper reports a specific and sensitive method for the detection of formyldienolone (FD) metabolites in man. The method is based on extraction of urine, derivatization of the steroids, and capillary GC-MS. The urinary excretion of the drug's metabolites has been investigated by using capillary GC-MS with SIM to monitor the metabolites' characteristic ions: ingestion of the drug can be easily proved 2-3 days after the administration of a single therapeutic dose.
This method is useful for doping control in sport and for studying the excretion and metabolism of anabolic steroids.
Experimental
Chemicals and Reagents
Esiclene tablets containing 5 mg of formyldienolone were obtained from LPB, Pharmaceutical Institute SPA, Cinisello Balsamo, Milan, Italy.
N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA), N-methyl-N-trimethylsilylheptafluorobutyramide (MSHFB), trimethylchlorosilane (TMSCl), and trimethylsilylimidazole (TSIM)
